<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=181456"><dc:title>Purine metabolism rewiring improves glioblastoma susceptibility to temozolomide treatment</dc:title><dc:creator>D'Aprile,	Simona	(Avtor)
	</dc:creator><dc:creator>Denaro,	Simona	(Avtor)
	</dc:creator><dc:creator>Torrisi,	Filippo	(Avtor)
	</dc:creator><dc:creator>Longhitano,	Lucia	(Avtor)
	</dc:creator><dc:creator>Giallongo,	Sebastiano	(Avtor)
	</dc:creator><dc:creator>Giallongo,	Cesarina	(Avtor)
	</dc:creator><dc:creator>Bontempi,	Vittorio	(Avtor)
	</dc:creator><dc:creator>Bucolo,	Claudio	(Avtor)
	</dc:creator><dc:creator>Drago,	Filippo	(Avtor)
	</dc:creator><dc:creator>Mione,	Maria Caterina	(Avtor)
	</dc:creator><dc:creator>Potokar,	Maja	(Avtor)
	</dc:creator><dc:creator>Jorgačevski,	Jernej	(Avtor)
	</dc:creator><dc:creator>Zorec,	Robert	(Avtor)
	</dc:creator><dc:subject>metabolism</dc:subject><dc:subject>purine</dc:subject><dc:subject>glioblastoma</dc:subject><dc:subject>temozolomide</dc:subject><dc:subject>treatment</dc:subject><dc:description>Glioblastoma (GBM) is among the deadliest cancers, characterized by poor prognosis and median survival of 12-15 months post-diagnosis. Despite aggressive therapeutic regimens, GBM treatment is still an unmet clinical need due to heterogeneity, recurrencies, and resistance. Metabolic reshaping is emerging as a critical mechanism supporting cell proliferation and sustaining chemoresistance. In this study, we explored metabolic changes induced by chemotherapy in temozolomide (TMZ)-sensitive and TMZ-resistant GBM cell lines. We found that purine levels were altered in sensitive versus resistant GBM cells, highlighting a critical role of guanosine and inosine metabolism. By using a mesenchymal-like GBM zebrafish model, we uncovered dysregulated pathways involved in purine metabolism, with a downregulation of catabolic processes. Our data indicate that combined treatment with TMZ plus guanosine and inosine increased cytotoxicity, enhancing chemotherapy effectiveness in TMZ-resistant cells. These effects correlated with alterations in mitochondrial dynamics and activity. Specifically, the combinatorial effectiveness of TMZ with guanosine and inosine was linked to Mitofusin-2 overexpression, enhancing mitochondrial fusion, typically associated with a better prognosis. Therefore, our findings suggest that purine metabolism is involved in the metabolic rewiring of TMZ-resistant cells, suggesting guanosine and inosine as potential adjuvant treatments to improve the cytotoxicity effects of chemotherapy in resistant GBM.</dc:description><dc:date>2025</dc:date><dc:date>2026-04-08 11:12:45</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>181456</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
